298 related articles for article (PubMed ID: 24122286)
1. Circulating biomarkers in patients with heart failure and preserved ejection fraction.
O'Meara E; de Denus S; Rouleau JL; Desai A
Curr Heart Fail Rep; 2013 Dec; 10(4):350-8. PubMed ID: 24122286
[TBL] [Abstract][Full Text] [Related]
2. Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review.
Garg A; Virmani D; Agrawal S; Agarwal C; Sharma A; Stefanini G; Kostis JB
Cardiology; 2017; 136(3):192-203. PubMed ID: 27784010
[TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
4. Novel biomarkers in heart failure with preserved ejection fraction.
Shah KS; Maisel AS
Heart Fail Clin; 2014 Jul; 10(3):471-9. PubMed ID: 24975910
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis of acute heart failure and relevance of biomarkers in elderly patients].
Ruiz Ortega RA; Manzano L; Montero-Pérez-Barquero M
Med Clin (Barc); 2014 Mar; 142 Suppl 1():20-5. PubMed ID: 24930079
[TBL] [Abstract][Full Text] [Related]
6. Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction.
Cypen J; Ahmad T; Testani JM; DeVore AD
Curr Heart Fail Rep; 2017 Oct; 14(5):434-443. PubMed ID: 28803400
[TBL] [Abstract][Full Text] [Related]
7. Emerging biomarkers in heart failure.
van Kimmenade RR; Januzzi JL
Clin Chem; 2012 Jan; 58(1):127-38. PubMed ID: 22086968
[TBL] [Abstract][Full Text] [Related]
8. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
Zile MR; Jhund PS; Baicu CF; Claggett BL; Pieske B; Voors AA; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754625
[TBL] [Abstract][Full Text] [Related]
9. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction.
van Woerden G; Gorter TM; Westenbrink BD; Willems TP; van Veldhuisen DJ; Rienstra M
Eur J Heart Fail; 2018 Nov; 20(11):1559-1566. PubMed ID: 30070041
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach.
Hage C; Michaëlsson E; Linde C; Donal E; Daubert JC; Gan LM; Lund LH
Circ Cardiovasc Genet; 2017 Feb; 10(1):. PubMed ID: 28100627
[TBL] [Abstract][Full Text] [Related]
11. Non-natriuretic peptide biomarkers in heart failure with preserved and reduced ejection fraction.
Oikonomou E; Vogiatzi G; Tsalamandris S; Mourouzis K; Siasos G; Lazaros G; Skotsimara G; Marinos G; Vavuranakis M; Tousoulis D
Biomark Med; 2018 Jul; 12(7):783-797. PubMed ID: 29865857
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of heart failure with normal ejection fraction: a systematic review.
Cheng JM; Akkerhuis KM; Battes LC; van Vark LC; Hillege HL; Paulus WJ; Boersma E; Kardys I
Eur J Heart Fail; 2013 Dec; 15(12):1350-62. PubMed ID: 23845797
[TBL] [Abstract][Full Text] [Related]
13. Soluble ST2 and galectin-3 in heart failure.
Shah RV; Januzzi JL
Clin Lab Med; 2014 Mar; 34(1):87-97, vi-vii. PubMed ID: 24507789
[TBL] [Abstract][Full Text] [Related]
14. The partnership between renalase and ejection fraction as a risk factor for increased cardiac remodeling biomarkers in chronic heart failure patients.
Stojanovic D; Mitic V; Stojanovic M; Petrovic D; Ignjatovic A; Stefanovic N; Cvetkovic T; Kocic G; Bojanic V; Deljanin Ilic M
Curr Med Res Opin; 2020 Jun; 36(6):909-919. PubMed ID: 32297799
[No Abstract] [Full Text] [Related]
15. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
[TBL] [Abstract][Full Text] [Related]
16. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction.
Gruson D; Lepoutre T; Ahn SA; Rousseau MF
Int J Cardiol; 2014; 172(1):e250-2. PubMed ID: 24467978
[No Abstract] [Full Text] [Related]
17. The use of biomarkers in the patient with heart failure.
Chowdhury P; Kehl D; Choudhary R; Maisel A
Curr Cardiol Rep; 2013 Jun; 15(6):372. PubMed ID: 23644993
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin.
Palazzuoli A; Masson S; Ronco C; Maisel A
Heart Fail Rev; 2014 Mar; 19(2):267-84. PubMed ID: 23563622
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover.
Martos R; Baugh J; Ledwidge M; O'Loughlin C; Murphy NF; Conlon C; Patle A; Donnelly SC; McDonald K
Eur J Heart Fail; 2009 Feb; 11(2):191-7. PubMed ID: 19168518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
